23.22
0.01 (0.04%)
| 前收盘价格 | 23.21 |
| 收盘价格 | 23.30 |
| 成交量 | 202,316 |
| 平均成交量 (3个月) | 817,124 |
| 市值 | 1,075,195,136 |
| 预期市盈率 (P/E Forward) | 9.49 |
| 价格/销量 (P/S) | 1.75 |
| 股市价格/股市净资产 (P/B) | 1.59 |
| 52周波幅 | |
| 利润日期 | 28 Jul 2025 - 1 Aug 2025 |
| 营业毛利率 | -14.76% |
| 营业利益率 (TTM) | 4.63% |
| 稀释每股收益 (EPS TTM) | -2.24 |
| 季度收入增长率 (YOY) | 1.10% |
| 季度盈利增长率 (YOY) | -46.40% |
| 总债务/股东权益 (D/E MRQ) | 79.70% |
| 流动比率 (MRQ) | 2.41 |
| 营业现金流 (OCF TTM) | 175.75 M |
| 杠杆自由现金流 (LFCF TTM) | 144.75 M |
| 资产报酬率 (ROA TTM) | 3.56% |
| 股东权益报酬率 (ROE TTM) | -12.27% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Pacira BioSciences, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.75 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 1.79% |
| 机构持股比例 | 110.89% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合